☆ 4.8 Article

Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine

FRONTIERS IN IMMUNOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Allergy

Correlation of Serum Levels of Interleukine-16, CCL27, Tumor Necrosis Factor-related Apoptosis-inducing Ligand, and B-cell Activating Factor with Multiple Sclerosis Severity

Ebrahim Kouchaki et al.

Summary: The serum levels of IL-16, CCL27, TRAIL, and BAFF were found to be elevated in patients with MS and positively correlated with disease severity. These findings contribute to a further understanding of the pathogenesis of MS and suggest potential new treatments.

IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Humoral- and T-Cell Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

Carla Tortorella et al.

Summary: This study evaluated the immune-specific response after full SARS-CoV-2 vaccination in patients with multiple sclerosis (MS) treated with different disease-modifying drugs. The results showed that mRNA vaccines induced both humoral and cell-mediated specific immune responses against viral spike proteins in the majority of patients with MS. These findings have important implications for promoting vaccination in all MS patients.

NEUROLOGY (2022)

添加到收藏夹

Article Immunology

B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications

Marco Iannetta et al.

Summary: This study analyzed the cell-mediated immune responses in multiple sclerosis patients who received the mRNA vaccine, revealing differences in antibody levels and peripheral blood lymphocyte counts among patients on different drug treatments.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function

Joseph J. Sabatino et al.

Summary: A comprehensive comparison of the effects of MS DMTs on SARS-CoV-2 vaccine-specific immunity is needed, including quantitative and functional B and T cell responses.

JCI INSIGHT (2022)

添加到收藏夹

Article Allergy

Modulation of Immune Responses against HA1 Influenza Vaccine Candidate by B-lymphocyte Stimulator Cytokine in Mice

Seyedeh Mahsa Bagheri Yazdi et al.

Summary: The study showed that the combination immunization of rBAFF-R with rHA1 can enhance the immune response against H1N1 influenza virus. However, the combined immunization did not promote T cell proliferation response. The combination of rBAFF-R/rHA1 provides effective protection, and lower doses of rHA1 can also trigger immune responses.

IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?

Ana Zabalza et al.

Summary: Anti-CD20 and S1PRM modify the immunological responses to SARS-CoV-2 vaccines, with humoral response decreasing under these treatments and with longer duration, while patients on anti-CD20 can still present cellular responses even in the absence of antibodies.

MULTIPLE SCLEROSIS JOURNAL (2022)

添加到收藏夹

Review Clinical Neurology

Vaccination and immunotherapies in neuroimmunological diseases

Alexander Winkelmann et al.

Summary: Neuroimmunological diseases and their treatment can affect immune responses to vaccinations, so careful selection and management of vaccines are necessary during immunotherapy to reduce the risk of infection and protect patients from disease.

NATURE REVIEWS NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine

Livnat Brill et al.

Summary: This study demonstrates that multiple sclerosis patients treated with cladribine tablets have a sustained positive vaccine specific serology response following the second and third doses of the SARS-CoV-2 vaccine.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Article Clinical Neurology

Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis

Sammita Satyanarayan et al.

Summary: The impact of disease modifying therapies (DMTs) for multiple sclerosis (MS) on antibody response to COVID-19 vaccination varies. Some DMTs attenuated antibody response, while others had no impact or even enhanced antibody response.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Article Clinical Neurology

Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: Effects of disease modifying therapies

Mario Habek et al.

Summary: In patients with multiple sclerosis, those treated with ocrelizumab are less likely to develop humoral immunity after COVID-19 recovery or vaccination, but there is no difference in cellular immunity compared to other treatment groups. This suggests that pwMS still have a certain level of cellular immune protection even when receiving B-cell depleting therapy.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Article Immunology

Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy

Arnau Antoli et al.

Summary: The study found that SARS-CoV-2 vaccines are less effective in CVID phenotype and BCD patients compared to healthy individuals. Predictive factors of inadequate specific antibody response in CVID phenotype patients include low IgA values, low CD19+ peripheral B cells, low switched memory B cells, and a low CD4+/CD8+ ratio. Further studies are needed to understand the effectiveness of vaccines in immunocompromised patients and predictive factors of immune response failure.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

Virginia Palomares Cabeza et al.

Summary: This study evaluated the impact of a third SARS-CoV-2 vaccination on T-cell responses in patients with multiple sclerosis. In patients treated with ocrelizumab, a third vaccination boosted T-cell responses. However, no T-cell responses were detected after a second or third vaccination in patients treated with fingolimod.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)

添加到收藏夹

Article Immunology

COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections

Dejan Jakimovski et al.

Summary: Patients with multiple sclerosis and other neuroinflammatory disorders treated with anti-CD20 and S1P medications have lower humoral response after receiving anti-SARS-CoV-2 vaccinations, even with booster doses. The waning of humoral response post-vaccination also puts vaccinated individuals at a greater risk of breakthrough COVID-19 infections.

VACCINES (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Neutrophils recruited to immunization sites initiating vaccine-induced antibody responses by locally expressing BAFF

Yangyang Wang et al.

Summary: Neutrophils play a crucial role in immune responses, and it has been found that they can regulate antibody reactions induced by vaccines at immunization sites. Inhibiting BAFF in neutrophils can weaken B cell activation and antibody production.

ISCIENCE (2022)

添加到收藏夹

Article Geriatrics & Gerontology

Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents

Pablo Montejano-Hervas et al.

Summary: This study assessed the safety and effectiveness of the vaccine against SARS-CoV-2 in frail nursing home residents. The results showed that the vaccine is well tolerated and effective in elderly individuals, and the immunogenicity is maintained over a period of 6 months.

DRUGS & AGING (2022)

添加到收藏夹

Article Virology

Clinical characteristics and outcomes of healthcare workers with COVID-19 pre- and postvaccination

Fabio F. D. Filho et al.

Summary: This study retrospectively assessed the clinical characteristics and outcomes of healthcare workers (HCW) with COVID-19 before and after vaccination. It found that vaccination reduced the severity of infection, leading to fewer hospitalizations, ICU admissions, and deaths among vaccinated HCWs.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters

William L. Conte et al.

Summary: This study confirms that the use of Evusheld can increase the antibody response to SARS-CoV-2 in patients with multiple sclerosis who are undergoing B-cell depleting therapy, providing an alternative strategy for protection against COVID-19.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Article Clinical Neurology

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis

Emma C. Tallantyre et al.

Summary: This study investigated the immune response of multiple sclerosis patients after receiving COVID-19 vaccines. The results showed that approximately one third of the patients seroconverted after receiving the third vaccine, indicating the benefit of boosters in this group. Nearly 80% of the patients had a measurable immune response after the third vaccine.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Article Immunology

Evaluation of Immunogenicity to Three Doses of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Lung Transplant Patients

Mariasilvia Guardiani et al.

Summary: The aim of this study was to investigate the immune response in lung transplant patients after receiving the mRNA vaccine. The results showed that lung transplant patients had a lower serologic response to SARS-CoV-2 compared to healthy donors, as well as a lower percentage of certain T-cell subsets. However, some lung transplant patients were still able to mount a cellular response even without a positive humoral response.

VACCINES (2022)

添加到收藏夹

Article Cell Biology

TNF-a+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies

Kattria van der Ploeg et al.

Summary: This study explores the dynamics of SARS-CoV-2-specific CD4(+) T cells in COVID-19 patients and their correlation with neutralizing antibodies. The results show a shift in the quality of the CD4(+) T cell response over time, with TNF-alpha-producing cells becoming predominant. Higher percentages of TNF-alpha-producing CD4(+) T cells on day 28 correlate with higher levels of neutralizing antibodies. mRNA vaccination after SARS-CoV-2 infection enhances both IFN gamma and TNF-alpha-producing CD4(+) T cells.

CELL REPORTS MEDICINE (2022)

添加到收藏夹

Article Clinical Neurology

Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis

Tirisham Gyang et al.

Summary: This study demonstrates that patients with multiple sclerosis exhibit reduced neutralizing antibody response to SARS-CoV-2 mRNA vaccination, which is dependent on the status of disease modifying therapies. Predictive biomarkers for vaccine efficacy were also identified. Therefore, additional vaccination strategies may be necessary to achieve protective immunity in patients with multiple sclerosis.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2022)

添加到收藏夹

Article Clinical Neurology

Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study

Maria Antonella Zingaropoli et al.

Summary: This study investigated the infectious risk in MS patients treated with DMTs. The results showed that screening for infectious diseases and taking preventive measures before starting treatment helps to mitigate the risk of infection. Regular assessment of infectious risk during treatment can avoid discontinuing therapy and provide a higher degree of safety.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2022)

添加到收藏夹

Article Immunology

Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses

Ron Milo et al.

Summary: The study evaluated the impact of DMTs on immune responses in MS patients receiving SARS-CoV-2 vaccinations, showing that most DMT-treated patients developed humoral and T-cell responses following 2nd and 3rd vaccinations. However, certain therapies may lead to weakened immune responses, highlighting the need for tailored vaccination guidelines.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

添加到收藏夹

Article Cell Biology

Distinct roles of ICOS and CD40L in human T-B cell adhesion and antibody production

Zhicui Liu et al.

Summary: The study demonstrates the diverse roles of CD40-CD40L and ICOS-ICOSL in cell adhesion and IgG/IgM production during CD4+ T-B cell interactions, with ICOS-ICOSL ligation more likely to be engaged in cell adhesion while CD40-CD40L provides indispensable signal for B cell differentiation and IgG/IgM production. This information might be helpful for understanding the pathogenesis of SLE.

CELLULAR IMMUNOLOGY (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccines

C. Buddy Creech et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Immunology

Persistent cellular immunity to SARS-CoV-2 infection

Gaelle Breton et al.

Summary: Recovered individuals exhibit persistent polyfunctional SARS-CoV-2 antigen-specific memory, as well as enduring alterations in the relative overall numbers of CD4(+) and CD8(+) memory T cells, including cell division and expression of activation/exhaustion markers.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

添加到收藏夹

Review Immunology

Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies

Johann Seliner et al.

Summary: There are concerns about using immunodepleting agents to treat MS patients during the COVID-19 pandemic, with vaccination against SARS-CoV-2 potentially being a solution. This review summarizes the immunological effects of immune-depleting therapy and discusses the existing recommendations for limited use of these therapies during the pandemic, while also critically examining questions about vaccination for MS patients.

VACCINES (2021)

添加到收藏夹

Article Infectious Diseases

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach

Alessandra D'Abramo et al.

Summary: Prolonged B-cell depletion caused by anti-CD20 therapy impairs the adaptive immune response, leading to severe manifestations during COVID-19. Two patients under anti-CD20 therapy experienced prolonged and severe COVID-19 but were successfully treated with mAbs targeting the SARS-CoV-2 spike proteins.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Liane Rabinowich et al.

Summary: Liver transplant recipients showed significantly lower immunological response to the Pfizer-BioNTech SARS-CoV-2 mRNA-based vaccine, with less than half developing sufficient levels of antibodies and lower average antibody levels compared to healthy controls. Predictors for non-response included older age, renal function and immunosuppressive medications.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis

Camilo E. Fadul et al.

Summary: The study demonstrates that blocking CD40L is safe and well tolerated in patients with RRMS, while also increasing CD25 (+) T cells and promoting an anti-inflammatory cytokine response. These findings provide support for further research to evaluate the efficacy of CD40L blockade as a potential treatment for RRMS.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

添加到收藏夹

Article Immunology

ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients

Andrea Picchianti-Diamanti et al.

Summary: In RA patients, the majority developed antibody-specific and whole-blood spike-specific T-cell responses following COVID-19 mRNA vaccine administration, with stable disease activity. The magnitude of these specific responses depended on the immunosuppressive therapy administered.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

Maria Pia Sormani et al.

Summary: This study found that anti-CD20 treatment and fingolimod in MS patients led to reduced humoral response to mRNA vaccines. mRNA-1273 vaccine resulted in significantly higher antibody levels compared to BNT162b2, suggesting it may be preferred for patients under certain treatments.

EBIOMEDICINE (2021)

添加到收藏夹

Article Microbiology

Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine

Chiara Agrati et al.

Summary: The study demonstrates that the BNT162b2 mRNA vaccine can induce both humoral and cell-mediated immune responses against spike peptides in nearly all healthcare workers without previous SARS-CoV-2 infection, with a moderate inverse correlation with age in the anti-RBD response.

MICROORGANISMS (2021)

添加到收藏夹

Article Immunology

COVID-19 in Lung Transplant Recipients

Jonathan Messika et al.

Summary: The COVID-19 infection in the French cohort of lung transplant patients was severe, with most cases requiring hospitalization and a survival rate of 85.7%. Among the critically ill patients, invasive mechanical ventilation was required for over half, and thrombotic events occurred in 4 patients. Overweight was significantly associated with the risk of death.

TRANSPLANTATION (2021)

添加到收藏夹

Article Clinical Neurology

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Anat Achiron et al.

Summary: The study found that after receiving the COVID-19 vaccine, MS patients who were either untreated or treated with cladribine showed a high level of protective humoral immunity, similar to healthy subjects. However, only a small percentage of MS patients treated with ocrelizumab and fingolimod developed a humoral immune response.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

添加到收藏夹

Article Medicine, General & Internal

A Novel Coronavirus from Patients with Pneumonia in China, 2019

Na Zhu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Virology

JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis

Maria Rosa Ciardi et al.

VIROLOGY JOURNAL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Takuya Sekine et al.

CELL (2020)

添加到收藏夹

Review Clinical Neurology

Effects of MS disease-modifying therapies on responses to vaccinations: A review

John Robert Ciotti et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

添加到收藏夹

Article Immunology

LT-K63 Enhances B Cell Activation and Survival Factors in Neonatal Mice That Translates Into Long-Lived Humoral Immunity

Audur Anna Aradottir Pind et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Review Immunology

B cell targeting by molecular adjuvants for enhanced immunogenicity

Taylor Sicard et al.

EXPERT REVIEW OF VACCINES (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice

Fabrizio Cantini et al.

EXPERT OPINION ON DRUG SAFETY (2019)

添加到收藏夹

Article Clinical Neurology

A proliferation-inducing ligand-mediated anti-inflammatory response of astrocytes in multiple sclerosis

Laurie Baert et al.

ANNALS OF NEUROLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients

Marco Iannetta et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Editorial Material Immunology

Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis

Maria R. Ciardi et al.

OPEN FORUM INFECTIOUS DISEASES (2019)

添加到收藏夹

Review Clinical Neurology

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters

Nicholas Schwab et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

添加到收藏夹

Review Clinical Neurology

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters

Nicholas Schwab et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

添加到收藏夹

Article Biotechnology & Applied Microbiology

JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus

Maria A. Zingaropoli et al.

BIOMED RESEARCH INTERNATIONAL (2018)

添加到收藏夹

Article Immunology

Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients

Chiara D'Angelo et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease

Darius Haeusler et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)

添加到收藏夹

Article Immunology

Functions of CD40 and Its Ligand, gp39 (CD40L)

Jon D. Leman et al.

CRITICAL REVIEWS IN IMMUNOLOGY (2017)

添加到收藏夹

Review Microbiology

The Role of BAFF System Molecules in Host Response to Pathogens

Jiro Sakai et al.

CLINICAL MICROBIOLOGY REVIEWS (2017)

添加到收藏夹

Review Clinical Neurology

Classification, diagnosis, and differential diagnosis of multiple sclerosis

Ilana Katz Sand

CURRENT OPINION IN NEUROLOGY (2015)

添加到收藏夹

Article Biotechnology & Applied Microbiology

COMPASS identifies T-cell subsets correlated with clinical outcomes

Lin Lin et al.

NATURE BIOTECHNOLOGY (2015)

添加到收藏夹

Article Clinical Neurology

JC-virus seroconversion in multiple sclerosis patients receiving natalizumab

Olivier Outteryck et al.

MULTIPLE SCLEROSIS JOURNAL (2014)

添加到收藏夹

Review Immunology

Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes

Andrea Cerutti et al.

NATURE REVIEWS IMMUNOLOGY (2013)

添加到收藏夹

Article Immunology

Stromal Endothelial Cells Establish a Bidirectional Crosstalk with Chronic Lymphocytic Leukemia Cells through the TNF-Related Factors BAFF, APRIL, and CD40L

Montserrat Cols et al.

JOURNAL OF IMMUNOLOGY (2012)

添加到收藏夹

Article Oncology

Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged

Yu Cheng Tang et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)

添加到收藏夹

Review Immunology

Cracking the BAFF code

Fabienne Mackay et al.

NATURE REVIEWS IMMUNOLOGY (2009)

添加到收藏夹

Review Immunology

T-cell quality in memory and protection: implications for vaccine design

Robert A. Seder et al.

NATURE REVIEWS IMMUNOLOGY (2008)

添加到收藏夹

Article Immunology

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

MB Litinskiy et al.

NATURE IMMUNOLOGY (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.